|Day Low/High||3.06 / 3.17|
|52 Wk Low/High||2.53 / 3.96|
Record Quarterly Revenue of $28.4 Million - Double Second Quarter 2018 Revenue The Company Increases Full Year 2019 Revenue Guidance to a Range of $100.
While the portfolio experienced some pain last week along with the broader market, 12 of our holdings beat the Russell 2000 either on an absolute or relative basis.
We exited a position last week for a nice gain as the market continued to rise.
As the momentum of earnings season rose last week, we made several trades including initiating a new position in Innovative Solutions and Support.
We added to one position last week as as the small-cap heavy Russell 2000 dipped.
We added to one position and initiated another during a shortened holiday week.
We initiated a new position and added to a couple of others as we closed the books on the second quarter.
Investors in Antares Pharma Inc. saw new options begin trading this week, for the February 2020 expiration.
Last week we started two new positions, trimmed a winner and exited another name as the markets moved higher across the board.
With the market rising last week, we saw favorable action in several of our holdings and booked some hefty gains in one name.
With the market rebounding, the majority of our positions rose week over week.
During the week, we exited our position in KushCo Holdings and initiated Antares Pharma.
We will close out KushCo Holdings, largely replacing it with an initial position in Antares Pharma.
There’s enough to like about Antares Pharma to keep an eye on it.
Investors in Antares Pharma Inc. saw new options begin trading this week, for the June 21st expiration.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ALRM, ATRS, CCK, CGC, FHN, FLGT, FND, GIFI, GTS, IMKTA, IONS, IROQ, LAWS, LEG, MANH, MOFG, NMFC, NPTN, NWN, RUN, VAC, WAL, XRAY Downgrades: ACHC, CNCE, HCI, ORBC, VMW Initiations: ALTR, FNKO, SE Read on to get TheStreet Quant Ratings' detailed report:
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Antares Pharma Inc. , where a total volume of 6,257 contracts has been traded thus far today, a contract volume which is representative of approximately 625,700 underlying shares (given that every 1 contract represents 100 underlying shares).
Complete Response Resubmission Accepted - PDUFA Date September 29, 2018
The Company Anticipates Second Quarter 2018 Resubmission
Record Annual Revenue of $54.5 Million
Investors in Antares Pharma Inc. saw new options become available this week, for the April 20th expiration.
AMAG Pharmaceuticals Makena® Subcutaneous Auto-Injector Approved To Reduce The Risk Of Preterm Birth In Certain At-Risk Women
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.